SCHEMBL4618971

SCHEMBL4618971

Cc1ccc(S(=O)(=O)c2ccc(F)cc2)cc1S(=O)(=O)NCC1CCOCC1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.47
CNR2 P34972 5/20 0.46
SFRP1 Q8N474 1/20 0.46
CNR1 P21554 1/20 0.44
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 1/20 0.42
NPC1 O15118 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
IDH2 P48735 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4619103 0.90 SFRP1 (0.58) CNR2SFRP1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL4617527 0.89 SFRP1 (0.49) TP53SFRP1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL4617904 0.88 CNR2 (0.45) CNR2SFRP1CNR1MEN1KMT2A
SCHEMBL4617752 0.86 HTR1A (0.47) CNR2CNR1MEN1KMT2ANPC1
SCHEMBL4617990 0.85 CNR2 (0.44) CNR2SFRP1CNR1ALDH1A1MEN1
SCHEMBL6102553 0.83 BRD4 (0.47) TP53SFRP1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL6102894 0.80 HTR1A (0.45) TP53CNR2CNR1MEN1KMT2A
SCHEMBL4618967 0.79 SFRP1 (0.61) SFRP1ALDH1A1SMN1; SMN2L3MBTL1LMNA
SCHEMBL6101464 0.78 PIK3CD (0.43) CNR2SFRP1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL4619595 0.78 ALDH1A1 (0.67) ALDH1A1L3MBTL1MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 TP53 4653/4885CNR2 3896/4885SFRP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.